AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21447587 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia without epidural block
Number of subjects: 503
Study 21447587 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block
Number of subjects: 503
Study 21447587 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epidural block)
Number of subjects: 503
Study 19793846 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/d anthocyanins as cyanidin glycosides (from elderberry) for 12 weeks
Number of subjects: 52
Study 19793846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 17005061 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 15
Study 17005061 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating Positive Expiratory Pressure (oscillating PEP)
Number of subjects: 15
Study 15213709 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules (containing Lactobacillus acidophilus and Bifidobacterium longum)
Number of subjects: 34
Study 15213709 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 34
Study 10997466 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture-mediated closure device
Number of subjects: 100
Study 10997466 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 100
Study 9338927 — intervention group
Group type: EXPERIMENTAL
Intervention: B. Amor's criteria
Number of subjects: 841
Study 9338927 — intervention group
Group type: EXPERIMENTAL
Intervention: ESSG criteria
Number of subjects: 841
Study 9338927 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of spondylarthropathy
Number of subjects: 841
Study 9338927 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 841
Study 8422624 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM-S (5-fluorouracil, doxorubicin, mitomycin C, and streptozotocin)
Number of subjects: 153
Study 8422624 — intervention group
Group type: COMPARATOR
Intervention: Phase II single agents (MGBG, DHAD, AZQ)
Number of subjects: 153
Study 3521208 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide
Number of subjects: 26
Study 3521208 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide
Number of subjects: 26
Study 3521208 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide plus 37.5 mg triamterene
Number of subjects: 26
Study 3521208 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide plus 75 mg triamterene
Number of subjects: 26
Study 3521208 — intervention group
Group type: COMPARATOR
Intervention: Control (run-in period)
Number of subjects: 26
Study 30552248 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich brown seaweed extract (2000 mg dose containing 600 mg polyphenols)
Number of subjects: 58
Study 30552248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2000 mg rice flour)
Number of subjects: 58
Study 27416102 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone ISM 50 mg
Number of subjects: 36
Study 27416102 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone ISM 75 mg
Number of subjects: 36
Study 27416102 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone ISM 100 mg
Number of subjects: 36
Study 27416102 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone ISM (all doses)
Number of subjects: 36
Study 26692164 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-Free Diet (GFD)
Number of subjects: 0
Study 26692164 — intervention group
Group type: EXPERIMENTAL
Intervention: GFD
Number of subjects: 0
Study 24351996 — intervention group
Group type: EXPERIMENTAL
Intervention: Enneagram group counseling program (38 hours, 8 sessions)
Number of subjects: 63
Study 24351996 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 63
Study 20202147 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 mcg/day
Number of subjects: 60
Study 20202147 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 mcg/day
Number of subjects: 60
Study 20202147 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5 or 10 mg tablet according to age
Number of subjects: 60
Study 20202147 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 60
Study 20202147 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 60
Study 18284403 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate (MPA) 0.1% cream twice weekly plus emollient (Advabase)
Number of subjects: 221
Study 18284403 — intervention group
Group type: COMPARATOR
Intervention: Emollient alone
Number of subjects: 221
Study 15665203 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic needle treatment
Number of subjects: 59
Study 15665203 — intervention group
Group type: COMPARATOR
Intervention: Placebo needle treatment
Number of subjects: 59
Study 12856118 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolaemic HVHF (6 l/h of replacement fluid) with varying pre-dilution rates
Number of subjects: 8
Study 10096930 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment consisting of omeprazole, clarithromycin, and tinidazole in H pylori-positive patients and clarithromycin alone in C pneumoniae-positive patients.
Number of subjects: 84
Study 10096930 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 84
Study 8902551 — intervention group
Group type: COMPARATOR
Intervention: Placebo (withdrawal group W, n = 12)
Number of subjects: 20
Study 8902551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril at previous doses (treated group T, n = 8)
Number of subjects: 20
Study 1866017 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 6
Study 1866017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30219454 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaungo applied twice a day for 3 weeks (treatment group 1)
Number of subjects: 28
Study 30219454 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaungo and placebo applied once a day for 3 weeks (treatment group 2)
Number of subjects: 28
Study 30219454 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice a day for 3 weeks (placebo group)
Number of subjects: 28
Study 30219454 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 28
Study 26984485 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya-maize-sorghum ready-to-use therapeutic food (SMS-RUTF)
Number of subjects: 0
Study 26984485 — intervention group
Group type: COMPARATOR
Intervention: Standard peanut paste-based ready-to-use therapeutic food (P-RUTF)
Number of subjects: 0
Study 26984485 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RUTFs
Number of subjects: 0
Study 24932147 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal expiratory positive airway pressure (NEPAP)
Number of subjects: 14
Study 24932147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 23227307 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Tacrolimus (LD) with EC-MPS 720mg bid
Number of subjects: 292
Study 23227307 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose Tacrolimus (SD) with EC-MPS 720mg bid
Number of subjects: 292
Study 20394511 — intervention group
Group type: EXPERIMENTAL
Intervention: Written and verbal information
Number of subjects: 52
Study 20394511 — intervention group
Group type: EXPERIMENTAL
Intervention: Written and verbal information with physical demonstration
Number of subjects: 52
Study 20394511 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical demonstration
Number of subjects: 52
Study 20394511 — intervention group
Group type: COMPARATOR
Intervention: Written and verbal information alone
Number of subjects: 52
Study 18396035 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg morphine + 5 mg ketamine/bolus (MK group)
Number of subjects: 57
Study 18396035 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg morphine/bolus (MO group)
Number of subjects: 57
Study 18396035 — intervention group
Group type: EXPERIMENTAL
Intervention: Subanaesthetic ketamine plus 2/3 the standard dose of morphine
Number of subjects: 57
Study 15745926 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid treatment
Number of subjects: 6
Study 15745926 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 6
Study 12617614 — intervention group
Group type: EXPERIMENTAL
Intervention: Buckwheat honey (1.5 g/kg body weight)
Number of subjects: 0
Study 12617614 — intervention group
Group type: COMPARATOR
Intervention: Corn syrup (1.5 g/kg body weight)
Number of subjects: 0
Study 12617614 — intervention group
Group type: EXPERIMENTAL
Intervention: Buckwheat honey (0.79 mg phenolic antioxidants per gram)
Number of subjects: 0
Study 12617614 — intervention group
Group type: EXPERIMENTAL
Intervention: Buckwheat honey (1.71 mg phenolic antioxidants per gram)
Number of subjects: 0
Study 11067718 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumo 23° pneumococcal vaccine
Number of subjects: 26000
Study 11067718 — intervention group
Group type: EXPERIMENTAL
Intervention: Older pneumococcal vaccines
Number of subjects: 26000
Study 8846980 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training (SIMT) 3 times a week for 3 months
Number of subjects: 10
Study 8846980 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 10
Study 1317764 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of lithium carbonate
Number of subjects: 10
Study 1317764 — intervention group
Group type: COMPARATOR
Intervention: 250 mg of lithium carbonate
Number of subjects: 10
Study 1317764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3904373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone (25, 50, and 75 micrograms/kg)
Number of subjects: 12
Study 3904373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3904373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone
Number of subjects: 12
Study 30340861 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (TAC)
Number of subjects: 120
Study 30340861 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5-fluorouracil (5-FU) and triamcinolone acetonide (TAC)
Number of subjects: 120
Study 29023174 — intervention group
Group type: EXPERIMENTAL
Intervention: SPRINT (4 × 30 second sprints separated by 4.5 minutes of active recovery)
Number of subjects: 16
Study 29023174 — intervention group
Group type: COMPARATOR
Intervention: MOD (20 minutes at 65% peak power output)
Number of subjects: 16
Study 26805720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 798
Study 26805720 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 798
Study 26805720 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 798
Study 24355576 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based smoking prevention program 'Smoke-free Kids' with five activity modules and one booster module after one year.
Number of subjects: 1478
Study 24355576 — intervention group
Group type: COMPARATOR
Intervention: Control condition received a fact-based intervention only.
Number of subjects: 1478
Study 22167716 — intervention group
Group type: EXPERIMENTAL
Intervention: Decremental test (DEC)
Number of subjects: 26
Study 22167716 — intervention group
Group type: EXPERIMENTAL
Intervention: Final incremental test (INC(F))
Number of subjects: 26
Study 22167716 — intervention group
Group type: COMPARATOR
Intervention: Control group (INC)
Number of subjects: 26
Study 20223557 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 5
Study 15761201 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy via facemask for 8 hours
Number of subjects: 16
Study 15761201 — intervention group
Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 16
Study 10849219 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion of 50 mU insulin/mL at 1 mL/h
Number of subjects: 0
Study 10849219 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion of 200 mU insulin/mL at 1 mL/h
Number of subjects: 0
Study 9380317 — intervention group
Group type: EXPERIMENTAL
Intervention: 21‐mg transdermal nicotine for 8 hours
Number of subjects: 14
Study 9380317 — intervention group
Group type: COMPARATOR
Intervention: Smoking ad libitum for 8 hours
Number of subjects: 14
Study 8230691 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg TNG solution (Solution group)
Number of subjects: 19
Study 8230691 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg TNG spray (Spray group)
Number of subjects: 19
Study 8230691 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 3083161 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face educational sessions with clinical pharmacists (2 sessions, average 18 minutes each)
Number of subjects: 435
Study 3083161 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 435
Study 29970639 — intervention group
Group type: EXPERIMENTAL
Intervention: Open face technique (Group A)
Number of subjects: 60
Study 29970639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sand-blasting technique (Group B)
Number of subjects: 60
Study 29970639 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparing retentive grooves technique (Group C)
Number of subjects: 60
Study 29970639 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 26458515 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% VO2 peak exercise
Number of subjects: 27
Study 26458515 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% VO2 peak exercise
Number of subjects: 27
Study 26458515 — intervention group
Group type: COMPARATOR
Intervention: No-exercise seated control
Number of subjects: 27
Study 23266839 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day
Number of subjects: 365
Study 20220746 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen-Placebo (AP)
Number of subjects: 134
Study 20220746 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen-Ondansetron (AO)
Number of subjects: 134
Study 20220746 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Placebo (PP)
Number of subjects: 134
Study 18586925 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy (combined modality treatment)
Number of subjects: 0
Study 18586925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 0
Study 16677798 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotin 61.4 micromol/day for 28 days
Number of subjects: 33
Study 16677798 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 28 days
Number of subjects: 33
Study 12880507 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 61
Study 11219367 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised injectable methadone maintenance treatment (MMT)
Number of subjects: 40
Study 11219367 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone maintenance treatment (MMT)
Number of subjects: 40
Study 9379379 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol 0.5% gel (Timoptic XE)
Number of subjects: 60
Study 9379379 — intervention group
Group type: COMPARATOR
Intervention: Oral, sustained‐release acetazolamide (Diamox Sequels)
Number of subjects: 60
Study 1327628 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg followed by 25 mg 2 h later)
Number of subjects: 6
Study 1327628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2427842 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 200 or 400 mg
Number of subjects: 58
Study 2427842 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40 or 80 mg
Number of subjects: 58
Study 29593018 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinothermy (35 L/min of 100% humidified air at 41°C via high flow nasal cannulae, 2 hours per day for up to 5 days)
Number of subjects: 30
Study 29593018 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinothermy
Number of subjects: 30
Study 29593018 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (250 mg daily for 5 days)
Number of subjects: 30
Study 27053325 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg/day for 10 days)
Number of subjects: 20
Study 27053325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24950358 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S+TRAP/AS02
Number of subjects: 83
Study 24950358 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAP/AS02
Number of subjects: 83
Study 24950358 — intervention group
Group type: COMPARATOR
Intervention: Challenge control
Number of subjects: 83
Study 22892455 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF at 250 µg/m days 1‐14 of a 28‐day cycle (Group A)
Number of subjects: 8
Study 22892455 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF at 250 µg 3 times a week continuously (Group B)
Number of subjects: 8
Study 21095333 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi plus ARB (ramipril plus candesartan)
Number of subjects: 72
Study 21095333 — intervention group
Group type: COMPARATOR
Intervention: ACEi plus β‐blockers (ramipril plus metoprolol)
Number of subjects: 72
Study 18678789 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 0.5 mg daily
Number of subjects: 414
Study 18678789 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1.0 mg daily
Number of subjects: 414
Study 18678789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study 18678789 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 414
Study 19330176 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐DTPA in AS patients
Number of subjects: 21
Study 15721575 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral avoidance tests with a harmless tarantula
Number of subjects: 0
Study 15721575 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral avoidance tests with a pen that had come in contact with the spider
Number of subjects: 0
Study 15721575 — intervention group
Group type: COMPARATOR
Intervention: Behavioral avoidance tests with a clean pen
Number of subjects: 0
Study 12413508 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 41
Study 12413508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9598252 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg.kg-1 rocuronium
Number of subjects: 42
Study 9598252 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg.kg-1 atracurium
Number of subjects: 42
Study 9598252 — intervention group
Group type: COMPARATOR
Intervention: 0.1 ml.kg-1 normal saline (placebo)
Number of subjects: 42
Study 8181203 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted heparin therapy
Number of subjects: 51
Study 8181203 — intervention group
Group type: COMPARATOR
Intervention: GUSTO heparin nomogram guidelines
Number of subjects: 51
Study 3119776 — intervention group
Group type: EXPERIMENTAL
Intervention: RX77368 (thyrotrophin releasing hormone analogue), iv over 2 hours
Number of subjects: 25
Study 3119776 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 25
Study 3119776 — intervention group
Group type: EXPERIMENTAL
Intervention: RX77368
Number of subjects: 25
Study 31933472 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg oral dose after 10 hours of fasting
Number of subjects: 36
Study 31933472 — intervention group
Group type: COMPARATOR
Intervention: Domperidone 10 mg oral dose 30 minutes after a high-fat meal
Number of subjects: 36
Study 29428486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular knee implantation of 40 million autologous bone marrow-derived MSCs per joint
Number of subjects: 30
Study 29428486 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 30
Study 27244782 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus brief individual CBT
Number of subjects: 212
Study 27244782 — intervention group
Group type: COMPARATOR
Intervention: TAU (control)
Number of subjects: 212
Study 23672806 — intervention group
Group type: EXPERIMENTAL
Intervention: Silmag(®)
Number of subjects: 100
Study 23672806 — intervention group
Group type: EXPERIMENTAL
Intervention: Bard(®)
Number of subjects: 100
Study 23672806 — intervention group
Group type: EXPERIMENTAL
Intervention: Freka(®)
Number of subjects: 100
Study 23672806 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo(®)
Number of subjects: 100
Study 23672806 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilson Cook(®)
Number of subjects: 100
Study 22646853 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender olfactory stimulation (n = 73)
Number of subjects: 145
Study 20946738 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of delinquency and violence exposure
Number of subjects: 732
Study 20946738 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower delinquency but independent-living placement
Number of subjects: 732
Study 20946738 — intervention group
Group type: EXPERIMENTAL
Intervention: African American adolescents
Number of subjects: 732
Study 20946738 — intervention group
Group type: EXPERIMENTAL
Intervention: White adolescents not close to caregivers
Number of subjects: 732
Study 20946738 — intervention group
Group type: EXPERIMENTAL
Intervention: White adolescents closer to caregivers with a history of psychological abuse
Number of subjects: 732
Study 18719218 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance
Number of subjects: 103
Study 18719218 — intervention group
Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 103
Study 15879357 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 38
Study 15879357 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen discontinuation after 28 days
Number of subjects: 38
Study 15879357 — intervention group
Group type: COMPARATOR
Intervention: Control group of 38 healthy women matched for age and menopausal status
Number of subjects: 38